Skip to Content

Precision Medicine Pioneer

Herceptin, the original genetic drug, showed that not all cancers are alike.

Herceptin is the original targeted drug therapy. The medication, which targets the HER2 protein associated with an aggressive form of breast cancer, was developed by the biotech company Genentech and won approval from the U.S. Food and Drug Administration in 1998. It has been used to treat more than two million patients worldwide and has generated global sales of more than $64 billion for the Swiss pharma giant Roche, which owns Genentech and markets Herceptin outside the U.S. Here’s how the pioneer of precision medicine has evolved. 

1985
National Institutes of Health shows that HER2 gene is frequently amplified in human breast tumor cells.

1990
Genentech scientists, having cloned the first human HER2 gene earlier, create Herceptin by humanizing a mouse antibody directed at HER2. Third parties later estimate Genentech’s development costs to be $150 to $200 million.

1992
Genentech requests authorization from the FDA to administer Herceptin as an investigational drug.

1992–1998
Clinical trials look at the safety and efficacy of Herceptin alone or with chemotherapy for people with HER2-positive metastatic breast cancer.

March 1998
Genentech announces collaboration with diagnostics company Dako to develop commercial test to identify patients who overexpress HER2.

May 1998
Genentech requests FDA permission to market Herceptin. FDA designates it a “Fast Track” and “Priority Review” product, which means it fills an unmet medical need for a serious condition and will be reviewed within six months rather than the standard 10.

September 1998
FDA approves Herceptin for the treatment of HER2-positive metastatic breast cancer and approves a diagnostic test to help identify patients.

August 2000
First European approval.

2006–2008
FDA approves three different Herceptin-­based regimens for post-surgery treatment of early-stage HER2-positive breast cancer. Approval for gastric cancer follows.

2014
First patent for Herceptin expires in Europe. Following the lead of an Indian biotech firm that got a highly similar version of the drug approved in 2013, a South Korean company receives approval for a “biosimilar” that shows no clinically meaningful difference in safety or effectiveness from the original product. Other Asian approvals follow.

May 2015
Shortly after President Obama announces his $215 million research project on precision medicine, the World Health Organization adds Herceptin to its list of essential medicines for low- and middle-income countries.

2019
First patent for Herceptin is scheduled to expire in the U.S.

Keep Reading

Most Popular

computation concept
computation concept

How AI is reinventing what computers are

Three key ways artificial intelligence is changing what it means to compute.

still from Embodied Intelligence video
still from Embodied Intelligence video

These weird virtual creatures evolve their bodies to solve problems

They show how intelligence and body plans are closely linked—and could unlock AI for robots.

We reviewed three at-home covid tests. The results were mixed.

Over-the-counter coronavirus tests are finally available in the US. Some are more accurate and easier to use than others.

conceptual illustration showing various women's faces being scanned
conceptual illustration showing various women's faces being scanned

A horrifying new AI app swaps women into porn videos with a click

Deepfake researchers have long feared the day this would arrive.

Stay connected

Illustration by Rose WongIllustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.